Charged lipids and uses for the same

Details Charged lipids and uses for the same Charged lipids and uses for the same

2002-01-15

2004-10-26

Hartley, Michael G. (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C424S009520, C424S009510, C424S502000

Reexamination Certificate

active

06808720

ABSTRACT:

FIELD OF THE INVENTION
The present invention is directed to charged lipids, compositions comprising charged lipids, and the use of these compositions in drug delivery, targeted drug delivery, therapeutic imaging and diagnostic imaging, as well as their use as contrast agents.
BACKGROUND OF THE INVENTION
To improve drug delivery, lessen toxicity and improve efficacy, various drug delivery systems have been devised. Drug delivery systems have included liposomes which are generally composed of neutral or zwitterionic lipids. The lipids in liposomes arrange themselves into bilayers and entrap one (unilamellar) or more (oligo- or multilamellar) spaces. The spaces between the bilayers of the lipids are usually filled with water. In conventional water filled liposomes, drugs are usually entrapped in the internal aqueous space, although in some cases they may be incorporated in the wall forming materials of the lipid bilayer. In conventional liposomes, it is often difficult to entrap a high concentration of a drug. Relying upon the internal entrapment of the drug, the efficiency necessarily depends upon the volume of fluid outside of the liposomes and circumscribed within the internal aqueous vesicular space. To improve the efficiency of drug entrapment, various techniques, such as ionic or pH gradients, have been employed. Still, the efficiency of drug encapsulation is less than desired. On long term storage, drugs entrapped within liposomes may leak out of the internal aqueous space into the surrounding milieu. The drug may therefore be lost from its desired intra-liposomal location. This is particularly problematic when there is a high concentration of drug entrapped within the liposomes and there is an osmotic gradient across the bilayer membrane. New and better methods of entrapping drugs in liposomes would be beneficial.
Studies have described the effects of calcium and other multivalent cations on membrane asymmetry, lipid distribution, vesicle size, aggregation and fusion. Although the underlying physical causes for the phenomena are debatable, general consensus exists that multivalent cations, such as calcium and magnesium, in the external environment of phospholipid vesicles cause the structures to aggregate into larger, multilamellar structures and promotes fusion. Barium and strontium ions have also been investigated in this regard. Duzgunes et al.,
Biochemistry,
23:3486-3494 (1984). Species of phospholipids that are particularly pronounced in these effects are the subjet of investigation, as described, for example, by Leckband, et al.,
Biochemistry
32:1127-1140 (1993), Tilley et al.,
Biogenic Amines,
5:69-74 (1988) and Kwon, et al.,
Colloids and Surfaces B,
3:25-30 (1994).
Other areas of investigation focused on the effect of calcium-induced aggregation on phase transition temperature and whether aggregation and fusion phenomena have a temperature dependance. Duzgunes, supra, Kwon, supra, and Tilcock et al.,
Biochemistry,
23:2696-2703 (1984). The effects of calcium-induced aggregation are so pronounced that efforts have been undertaken to limit the effect in order to control the size of liposomes used in drug delivery systems by forming vesicles in which calcium ions are confined to outer surfaces of the bilayer. European Patent Publication EP 579 703.
Another form of prior art has been the development of polymeric microspheres. Polymeric microspheres may retain the drugs to a better extent than liposomes, but there may be problems with biodegradability and toxicity.
The present invention is directed to, among other things, the development of new and improved drug and contrast media delivery systems that overcome the problems associated with the prior art.
SUMMARY OF THE INVENTION
The present invention describes methods of delivering bioactive agents to a patient and/or treating conditions in a patient comprising administering to the patient a composition comprising a charged lipid, a counter ion, a lipid covalently bonded to a polymer and a bioactive agent, and applying therapeutic ultrasound to the patient to facilitate delivery of the bioactive agent in a desired region of the patient. If desired, the methods may further comprise imaging the patient to monitor the location of the composition. The composition may further comprise, for example, one or more of neutral lipids, charged lipids, gases, gaseous precursors, liquids, oils, diagnostic agents, targeting ligands and/or other bioactive agents.
The present invention describes methods of delivering bioactive agents to a patient and/or treating conditions in a patient comprising administering to the patient a composition comprising a charged lipid, a counter ion, a lipid covalently bonded to a polymer, a bioactive agent and a targeting ligand. If desired, the methods may further comprise imaging the patient to monitor the location of the composition and/or applying therapeutic ultrasound to the patient to facilitate delivery of the bioactive agent in a desired region of the patient. The composition may further comprise, for example, one or more of neutral lipids, charged lipids, gases, gaseous precursors, liquids, oils, diagnostic agents and/or other bioactive agents.
The present invention also describes methods of providing an image of an internal region of a patient comprising administering to the patient a composition comprising a charged lipid, an counter ion, and a lipid covalently bonded to a polymer. The methods may further comprise scanning the patient using diagnostic imaging to obtain visible images of the internal region of the patient. The composition may further comprise, for example, one or more of neutral lipids, charged lipids, gases, gaseous precursors, liquids, oils, diagnostic agents, targeting ligands and/or bioactive agents.
The present invention also describes methods of diagnosing the presence of diseased tissue in a patient comprising administering to the patient a composition comprising a charged lipid, a counter ion, and a lipid covalently bonded to a polymer. The methods may further comprise scanning the patient using diagnostic imaging to obtain a visible image of any diseased tissue in the patient. The composition may further comprise, for example, one or more of neutral lipids, charged lipids, gases, gaseous precursors, liquids, oils, diagnostic agents, targeting ligands and/or bioactive agents.
In addition, the present invention describes novel contrast agents comprising a charged lipid, a counter ion, and a lipid covalently bonded to a polymer. The contrast agents may further comprise, for example, one or more of neutral lipids, charged lipids, gases, gaseous precursors, liquids, oils, diagnostic agents, targeting ligands and/or bioactive agents.
These and other aspects of the invention will become apparent from the following detailed description.


REFERENCES:
patent: 3015128 (1962-01-01), Sommerville et al.
patent: 3293114 (1966-12-01), Kenaga et al.
patent: 3401475 (1968-09-01), Morehouse et al.
patent: 3479811 (1969-11-01), Walters
patent: 3488714 (1970-01-01), Walters et al.
patent: 3532500 (1970-10-01), Priest et al.
patent: 3594326 (1971-07-01), Himmel et al.
patent: 3615972 (1971-10-01), Morehouse et al.
patent: 3647784 (1972-03-01), Stein et al.
patent: 3649620 (1972-03-01), Ercoli et al.
patent: 3650831 (1972-03-01), Jungermann et al.
patent: 3732172 (1973-05-01), Herbig et al.
patent: 3873564 (1975-03-01), Schneider et al.
patent: 3945956 (1976-03-01), Garner
patent: 3960583 (1976-06-01), Netting et al.
patent: 3968203 (1976-07-01), Spitzer et al.
patent: 4027007 (1977-05-01), Messina
patent: 4078052 (1978-03-01), Papahadjopoulos
patent: 4089801 (1978-05-01), Schneider
patent: 4108806 (1978-08-01), Cohrs et al.
patent: 4138383 (1979-02-01), Rembaum et al.
patent: 4162282 (1979-07-01), Fulwyler et al.
patent: 4179546 (1979-12-01), Garner et al.
patent: 4192859 (1980-03-01), Mackaness et al.
patent: 4224179 (1980-09-01), Schneider
patent: 4229360 (1980-10-01), Schneider et al.
patent: 4265251 (1981-05-01), Tickner
patent: 4276885 (1981-07-01), Tickner et al.
patent: 4

Affiliated with

Also associated with

Rating

Charged lipids and uses for the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Charged lipids and uses for the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Charged lipids and uses for the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3300214